INTRODUCTION
Although Spacers have been shown to improve lung deposition, reduce side effects, and overcome challenges with inhaler coordination, they are often left at home due to their size and appearance.
METHODS
The survey was performed on-line by 86 patients who currently used a spacer after obtaining the new AeroChamber2go* 2-in-1 spacer and protective case. Participants were asked to report how often they used a spacer outside of the home before and after obtaining the new spacer, as well as to provide satisfaction levels of various attributes.
RESULTS
CONCLUSION
An initial post launch assessment had previously reported positive feedback following 1 month of use.
This new study confirmed continued usage and satisfaction over a prolonged period, therefore providing greater confidence in the sustainability of the benefits. The survey highlighted a substantial increase in use of spacer with pMDI ‘on-the-go’.
The spacer’s improved ease of use, carrying and convenience may well have contributed to the noted increased adherence. Use of such devices should be considered for all patients potentially requiring a reliever pMDI when ‘on-the-go’.
